Progress in immunotherapy for hepatocellular carcinoma
10.3969/j.issn.1006-0111.2017.04.019
- VernacularTitle:免疫治疗在肝细胞癌治疗中的进展
- Author:
Lingling GUO
1
;
Jinrong QIU
Author Information
1. 第二军医大学附属东方肝胆外科医院肿瘤生物治疗科
- Keywords:
hepatocellular carcinoma;
tumor immunotherapy;
DC;
PD-1 blockade;
PIK
- From:
Journal of Pharmaceutical Practice
2017;35(4):362-366
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma is a malignant tumor with high morbidity and mortality globally.The therapeutic results on hepatocellular carcinoma with surgery and other classical treatments are not satisfactory.Tumor immunotherapies, such as dendritic cells and cytokine-induced killer cells (DC-CIK), tumor-infiltrating lymphocytes (TIL), chimeric antigen receptor T cells (CAR-T), immune checkpoint blockade (such as PD-1 blockade,CTL4 blockade) etc., are very promising new therapeutic approaches.In this paper, the progresses in the immunotherapy, mainly on PD-1, DC-CIK, TIL, are reviewed.Also pluripotent immune killer cells (PIK) which was developed in our lab was briefly introduced.
